FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
BPC-157 / TB-500 Blend 5/5mg research peptide vial
Recovery

BPC-157 / TB-500 Blend

Dual recovery blend

A two-peptide research blend combining BPC-157 and TB-500.

From $120

In stock · ships in 1–2 business days

  • ✓ 99.05% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
blendrecovery

Research Summary

This blend combines BPC-157 and TB-500 in a single vial, the two peptides most frequently studied together in preclinical tissue-repair research. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

BPC-157 / TB-500 Blend: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is the BPC-157 / TB-500 Blend?

This product combines two research peptides, BPC-157 and TB-500, in one lyophilized vial. They are the two peptides most often discussed together in preclinical tissue-repair research, but they are unrelated molecules with different origins and proposed mechanisms. Each has its own research page: BPC-157 and TB-500.

Research on the specific combination of these two peptides in one vial is limited. Almost everything published concerns each peptide on its own, and the findings summarized below should be read that way. This page makes no claim that the two peptides interact, complement each other, or produce a combined effect.

BPC-157 / TB-500 Blend molecular identity
Component 1: BPC-157GEPPPGKPADDAGLV, 15 amino acids, C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957)
Component 2: TB-500Indexed by PubChem as Ac-LKKTETQ, the acetylated 17-23 fragment of thymosin beta-4, C38H68N10O14, 889.0 g/mol (PubChem CID 62707662)
TB-500 parent proteinThymosin beta-4, 43 amino acids, 4963 g/mol (PubChem CID 16132341)
Identity on current blend certificateBPC-157 and thymosin beta-4 (LC-MS, as reported by the testing laboratory)
FormLyophilized powder, both peptides combined in a single vial
Available strengths5mg/5mg and 10mg/10mg

The two components

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide reproducing part of a protein originally isolated from human gastric juice [1]. In rat tendon fibroblasts it increased cell migration and survival under oxidative stress, linked to phosphorylation of focal adhesion kinase and paxillin [3]. In endothelial cell and rodent models it was associated with VEGFR2-Akt-eNOS signaling and increased vessel density [4]. A 2025 systematic review in orthopaedic sports medicine found 36 studies, 35 of them preclinical, and concluded that BPC-157 should be regarded as investigational [5].

TB-500

TB-500 is associated with thymosin beta-4, a 43-residue actin-sequestering protein. PubChem and anti-doping laboratories describe TB-500 as Ac-LKKTETQ, an acetylated copy of residues 17 to 23 of thymosin beta-4 that include its central actin-binding domain [2] [6]. The name is also used for synthetic full-length thymosin beta-4. A 2010 review linked the LKKTETQ region of the parent protein to angiogenesis, wound healing, and cell migration in experimental systems [7]. Most published biology concerns the full-length protein, and those findings cannot automatically be attributed to the fragment. See the TB-500 page for a full discussion of identity.

What is known about the combination

We found one published study that compared BPC-157, TB-500, and both together within the same model. In a 2026 exploratory study of surgically repaired Achilles tendons in 32 rats, the TB-500 group showed higher maximum load to failure than controls at four weeks, and both single-peptide groups showed improved histological scores. The group that received both peptides did not show additional improvement compared with either peptide alone. The authors described the findings as preliminary [8].

That study gave the peptides as separate preparations in an animal model. It did not study a pre-combined vial, and no published study we found has characterized the stability or behavior of the two peptides stored together. Human evidence is very limited for BPC-157 and essentially absent for TB-500 as a fragment [5] [9]. Nothing here should be read as evidence of safety or benefit in people.

For background on each compound, see our BPC-157 research overview and browse other compounds in our tissue-repair research category.

Regulatory status

  • Not FDA approved. BPC-157 and TB-500 are unapproved peptides, not FDA-approved drugs [10].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) includes both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" among withdrawn nominations, with a possible risk of immunogenicity for certain routes of administration [9].
  • Advisory committee vote. At its July 23-24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend each of BPC-157 and TB-500 for the 503A bulks list, against the recommendation of FDA staff. These votes are non-binding, and FDA had not acted on them at the time of this review [10] [11].
  • Sport. The World Anti-Doping Agency 2026 Prohibited List names BPC-157 under S0 (non-approved substances) and "Thymosin-β4 and its derivatives e.g. TB-500" under S2.3 [12].

Rejuvatide supplies this blend strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

This blend has its own certificate from an independent laboratory, covering HPLC purity of the combined material, LC-MS identity of both components, and an endotoxin result under USP <85>. The current certificate was issued for a 10mg/10mg lot and names the components as BPC-157 and thymosin beta-4. It is shown below and in our COA library, published exactly as the laboratory issued it.

Storage of lyophilized material

The blend ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of BPC-157 / TB-500 Blend.

99.05%HPLC purity
Lot 60730-06Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

BPC-157 / TB-500 Blend FAQ

What is in the BPC-157 / TB-500 Blend?

Two research peptides in one lyophilized vial: BPC-157, a 15-residue gastric-protein fragment, and TB-500, a peptide associated with thymosin beta-4. It is offered in 5mg/5mg and 10mg/10mg strengths.

Has this combination been studied?

Only to a limited extent. One 2026 rat tendon study compared the two peptides alone and together and found no additional effect from combining them. No published study we found examined the two stored together in one vial.

Are BPC-157 and TB-500 the same molecule?

No. BPC-157 is a fragment of a gastric protein, while TB-500 is associated with the actin-binding protein thymosin beta-4. They are unrelated molecules with separate research literatures.

Is this blend FDA approved?

No. Neither component is FDA approved. An FDA advisory committee voted in July 2026 to recommend both peptides for the 503A compounding list, but those votes are non-binding and FDA had not acted on them as of October 12, 2026.

How is the blend tested?

The blend has its own independent laboratory certificate covering HPLC purity, LC-MS identity of both components, and endotoxin under USP <85>, published on this page and in the COA library.

Is this blend for human use?

No. Rejuvatide sells it for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. BPC 157, Compound CID 9941957. National Library of Medicine. Source
  2. PubChem. TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH), Compound CID 62707662. National Library of Medicine. Source
  3. Chang CH, Tsai WC, Lin MS, et al. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672
  4. Hsieh MJ, Liu HT, Wang CN, et al. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966
  5. Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025;21(4):485-495. PubMed 40756949
  6. Esposito S, Deventer K, Goeman J, et al. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027
  7. Sosne G, Qiu P, Goldstein AL, et al. FASEB J. 2010;24(7):2144-51. PubMed 20179146
  8. Biçer O, Adanir O, Güleryüz Y, et al. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926
  9. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  10. Pharmaceutical Executive. FDA panel votes to loosen restrictions on four peptides (July 24, 2026). Source
  11. Kelley Drye & Warren LLP. FDA advisory committee recommends several peptides for compounding for various uses despite staff opposition: what stakeholders need to know (July 30, 2026). Source
  12. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-Approved Substances and S2.3 Growth Factors and Growth Factor Modulators. Source